CLEVELAND and DALLAS, April 10, 2025 | Align Capital Partners’ (“ACP”) toxicology testing solutions provider Premier Biotech (“Premier” or the “Company”) completed two successive acquisitions including OraSure Technologies, Inc.’s (“OTI”) substance abuse testing business line (the “OraSure Toxicology Line”), and separately, the Mexican subsidiary of Green Earth Biomedical LLC (“GEM”), an international provider of drug testing solutions.
In November 2024, OTI announced that it was exiting the substance abuse testing business. In connection with that decision, on March 27, 2025, Premier acquired certain assets of OTI that make up the OraSure Toxicology Line, but not including the OraSure name or trademark.
Prior to its exit, OTI was a global leader in oral fluid substance abuse testing products serving the employment, forensic and substance abuse treatment markets. The OraSure Toxicology Lines’ unique assays provide accurate and easy-to-administer testing methods to help determine the presence, or absence, of drugs or alcohol in a person’s system. Oral fluid-based testing products provide a simplified collection process, faster results and cost savings, with minimal risk of tampering and dramatically reduced risk of adulteration. The OraSure Toxicology Line acquisition further solidifies Premier’s oral fluid leadership position in toxicology diagnostics and services; plus, expands Premier’s service offering and customer relationships.
“OTI’s substance abuse testing products are known for their quality, innovation, and most importantly, ease of use. While broadening Premier’s offerings, this acquisition reflects the Company’s unwavering commitment to expand the oral fluid market as a whole and enhance Premier’s oral fluid leadership position within the toxicology space. As the market continues to transition to oral fluid, we are building a complete set of diagnostic solutions and are thrilled to offer additional lab based oral fluid choices to the market,” said Premier CEO Matt Michalik.
GEM is a domestic and international distributor of drug testing solutions and Premier’s current international distributor in Mexico and Latin America. GEM is a very strategic acquisition that will allow Premier to accelerate its international expansion and serve the needs of customers in very challenging and complex markets.
Premier Biotech has completed three acquisitions since partnering with ACP in November of 2022. The Company will continue to pursue additional acquisitions and collaboration opportunities to further accelerate its growth. ACP Managing Partner Rob Langley, Operating Partner Ervin Cash, Principal Matt Bowen and Associate Sarah Mahosky worked alongside Premier Management on the transaction.